221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

Are biotech's fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices? STAT's Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of gene therapy who staffers say presided over a toxic, abusive workplace. We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry.